Nika Pharmaceuticals, Inc. (OTCQB: NIKA) Funding Update
Rhea-AI Summary
Nika Pharmaceuticals (OTCQB: NIKA) reports it is in ongoing negotiations with investors from several countries for potential financing of up to $50 million. The company aims to select a single suitable investor-partner and, according to management, targets finalizing a funding deal by September 30, 2026 to support its investment program.
Nika states that technical planning is complete and required equipment is selected, which it believes would allow rapid construction of a pharmaceutical manufacturing facility and a quick start of production once funds are received. The company also directs interested parties to a video presentation for more project details.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HENDERSON, Nev., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Nika Pharmaceuticals, Inc. (OTCQB: NIKA) is continuing its ongoing negotiation with investors from Thailand, Japan, Switzerland, Luxembourg, USA, Bulgaria, and the UAE for financing of up to 50 million US dollars. The Company has seen great interest, with most investors reaching out directly to NIKA.
“We are striving to select the most suitable investor and partner for NIKA, for which reason the discussions surrounding the technical details of the potential deals are taking more time”, stated CEO Dimitar Savov. “We are expecting to have made our final decision and finalized a funding deal by September 30th, so that we can secure the necessary capital for NIKA’s investment program.”
All technical planning is complete and all necessary equipment is selected, which will allow NIKA to construct the pharmaceutical manufacturing facility and begin production in a very short time following entry of funds. For a more comprehensive understanding regarding NIKA’s pharmaceutical project, watch the Company’s video investor presentation here: https://www.youtube.com/watch?v=E27N3VrXVNI.
About Nika Pharmaceuticals, Inc.
Nika Pharmaceuticals, Inc. (NIKA) is a pharmaceutical company, specializing in the treatment of HIV/AIDS, Hepatitis B and C, Rheumatoid Arthritis, Cancer, Diabetes, and all diseases, for which strengthened cell immunity is of vital importance. NIKA's intellectual property includes six drugs in injection form – two of which have successfully undergone clinical trials with good treatment results – four drugs in tablet form, and eleven dietary supplements. NIKA’s goal is to not only achieve corporate profits, but to provide better and easier access to life-saving medicinal drugs and useful dietary supplements. Find more on www.nikapharmaceuticals.com.
Forward-looking Statement:
This press release contains forward-looking statements. Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements.” These forward-looking statements generally are identified by the words “believes,” “estimates,” “intends,” “plan,” “can,” “will,” “would,” “expects,” and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain.
CONTACT Clifford Redekop, Secretary COMPANY Nika Pharmaceuticals, Inc. PHONE (702)-326-3615 EMAIL info@nikapharmaceuticals.com WEB www.nikapharmaceuticals.com